On February 20, 2025, Whitefort Capital Management, LP increased its position in Arbutus Biopharma Corp (NASDAQ: ABUS) by acquiring 66,051 shares, raising its stake to 13,307,967 shares, which represents 23.8% of its portfolio and 7% of Arbutus’s total shares. The transaction reflects Whitefort’s ongoing interest in biotechnology, particularly in innovative treatments for chronic diseases. Despite a market cap of $648.06 million, Arbutus is deemed overvalued with a low profitability rank. The company’s recent performance shows modest revenue growth, but mixed momentum signals raise caution regarding its financial health and future potential.